Literature DB >> 21122694

Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease.

Raja Shekhar R Sappati Biyyani1, Brian S Putka, Kevin D Mullen.   

Abstract

BACKGROUND: Dyslipidemia is a major risk factor for developing coronary artery disease. An increase in inflammatory cytokines may result in a decrease in lipoprotein lipase (LPL) enzyme activity, leading to a characteristic lipoprotein profile with increased triglycerides and decreased high-density lipoprotein (HDL) levels as seen in patients with systemic lupus erythematosus (SLE). Similar to SLE, patients with IBD have high circulatory levels of inflammatory cytokines. However, in these patients characteristic lipoprotein profiles have not been reported.
OBJECTIVES: The purpose of this study is to identify and describe dyslipidemia and lipoprotein profiles in an IBD patient population.
METHODS: Medical records of patients diagnosed with IBD (Crohn's disease [CD] and ulcerative colitis [UC]) at an academic medical center between 2000 and 2007 were retrospectively reviewed for lipoprotein lipid measurements, serum albumin levels, risk factors, and treatment to modify lipoprotein concentrations. The lipoprotein guidelines and risk factors are based on the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Only patients with documented IBD diagnosis and lipoprotein profiles are included in the study. National Health and Nutrition Examination Survey (NHANES) 2005-2006 population database was used for control values.
RESULTS: A total of 393 patients (152 men and 241 women) diagnosed with IBD (188 CD and 205 UC) who were not on statins qualified for the study. Patients were grouped on the basis of gender (male and female) and IBD disease type (CD and UC). Compared with the male NHANES samples (with similar mean age and body mass index), total cholesterol and HDL-C were significantly lower and low-density lipoprotein cholesterol (LDL-C) and triglycerides were significantly greater in male patients with IBD. In female patients with IBD, the mean values for total cholesterol, HDL-C, and triglycerides were significantly lower and LDL-C significantly greater compared with the female NHANES samples.
CONCLUSION: Given low levels of HDL-C and increased levels of LDL-C, a more aggressive approach in profiling and treating dyslipidemia seems warranted in patients with IBD.
Copyright © 2010 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122694     DOI: 10.1016/j.jacl.2010.08.021

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  33 in total

Review 1.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Dyslipidemia and inflammation in patients with inflammatory bowel disease.

Authors:  Fatih Karaahmet; Omer Basar; Sahin Coban; Ilhami Yuksel
Journal:  Dig Dis Sci       Date:  2013-03-16       Impact factor: 3.199

3.  Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.

Authors:  Efstratios Koutroumpakis; Claudia Ramos-Rivers; Miguel Regueiro; Jana G Hashash; Arthur Barrie; Jason Swoger; Leonard Baidoo; Marc Schwartz; Michael A Dunn; Ioannis E Koutroubakis; David G Binion
Journal:  Dig Dis Sci       Date:  2015-10-29       Impact factor: 3.199

4.  A new model for the discrimination between ulcerative colitis and Crohn's disease.

Authors:  Zhe Shen; Wei-Ping Ma; Xiao-Na Shao; Chao-Hui Yu; Juan Du; Zun Xiang; Gan-Hua Guo; Hong Zhang; You-Ming Li; Min Yue
Journal:  Int J Clin Exp Med       Date:  2015-01-15

5.  Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.

Authors:  José Miranda-Bautista; Celia de Gracia-Fernández; María López-Ibáñez; María Barrientos; Alejandra Gallo-Moltó; Marina González-Arias; Casilda González-Gil; Alicia Díaz-Redondo; Ignacio Marín-Jiménez; Luis Menchén
Journal:  Dig Dis Sci       Date:  2015-02-14       Impact factor: 3.199

6.  Epithelial Cholesterol Deficiency Attenuates Human Antigen R-linked Pro-inflammatory Stimulation via an SREBP2-linked Circuit.

Authors:  Seong-Hwan Park; Juil Kim; Mira Yu; Jae-Hong Park; Yong Sik Kim; Yuseok Moon
Journal:  J Biol Chem       Date:  2016-10-04       Impact factor: 5.157

Review 7.  Thromboembolic complications in inflammatory bowel disease.

Authors:  Darina Kohoutova; Paula Moravkova; Peter Kruzliak; Jan Bures
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

8.  Inhibition of Interleukin-10 Signaling Induces Microbiota-dependent Chronic Colitis in Apolipoprotein E Deficient Mice.

Authors:  Vishal Singh; Manish Kumar; Beng San Yeoh; Xia Xiao; Piu Saha; Mary J Kennett; Matam Vijay-Kumar
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 9.  Epidemiology, risk factors and management of cardiovascular diseases in IBD.

Authors:  Siddharth Singh; Iftikhar J Kullo; Darrell S Pardi; Edward V Loftus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

10.  The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.

Authors:  Tobias M Nowacki; Alan T Remaley; Dominik Bettenworth; Michel Eisenblätter; Thorsten Vowinkel; Felix Becker; Thomas Vogl; Johannes Roth; Uwe J Tietge; Andreas Lügering; Jan Heidemann; Jerzy-Roch Nofer
Journal:  Br J Pharmacol       Date:  2016-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.